The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers (DHEA)
Primary Purpose
Substance Withdrawal Syndrome
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
dehydroepiandrosterone (DHEA)
pregnenolone
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Substance Withdrawal Syndrome focused on measuring Cigarette Smokers, DHEA, dehydroepiandrosterone, pregnenolone, Nicotine withdrawal symptoms
Eligibility Criteria
Inclusion Criteria:
- male;
- 18-65 years old;
- smoked an average of at least 10 cigarettes per day for three cumulative or continuous years of a brand that delivers (by Federal Trade Commission rated yields) at least 0.5 mg nicotine;
- afternoon expired carbon monoxide reading of at least 10 ppm;
- in general good health, based on physical examination, EKG serum chemistries, CBC and urinalysis.
Exclusion Criteria:
- Participants must not have uncontrolled hypertension (systolic >140 mm Hg, diastolic >95 mm Hg)
- hypotension (systolic <90 mm Hg, diastolic <60 mm Hg);
- coronary heart disease;
- heart attack;
- cardiac rhythm disorder (irregular heart rhythm);
- chest pains (unless history, exam, and EKG clearly indicate a non-cardiac source);
- cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);
- liver or kidney disorder (except kidney stones, gallstones);
- gastrointestinal problems or disease other than gastroesophageal reflux,
- heartburn, or irritable bowel syndrome;
- ulcers within the past 6 months;
- lung disorder (including but not limited to COPD, emphysema, and asthma);
- brain abnormality (including but not limited to, stroke, brain tumor, seizure disorder);
- history of fainting;
- problems giving blood samples;
- diabetes;
- current cancer or treatment for cancer in the past 6 months (except basal or squamous cell skin cancer);
- other major medical condition;
- major depression, panic disorder, anxiety, bipolar disorder, schizophrenia, risk of suicide, or substance dependence other than nicotine dependence;
- subjects who endorse suicidal ideation on the MINI abridged;
- alcohol or drugs abuse;
- reported use of illicit drugs within the past 30 days, or if the drug screen is positive;
- reported use of smokeless tobacco (chewing tobacco, snuff), cigars, pipes, or nicotine replacement therapy; testosterone replacement therapy, DHEA or Pregnenolone; experimental (investigational) drugs; psychiatric medications (including antidepressants, anti-anxiety agents. anti-psychotics), sleep aids, medications that increase DHEA and/or DHEA-S concentrations (including, but not limited to: diltiazem, benfluorex, amlodipine, alprazolam, danazol, metformin, nitrendipine and retinol), or any other medications that are known to affect smoking (e.g. clonidine, muscle relaxants, opiate pain medications) within the past 2 weeks.
Sites / Locations
- Duke Center for Nicotine & Smoking Cessation Research
- Duke Center for Nicotine & Smoking Cessation Research
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Dehydroepiandrosterone (DHEA)
Pregnenolone
Placebo
Arm Description
Outcomes
Primary Outcome Measures
The administration of DHEA or pregnenolone will reduce smoking withdrawal symptoms.
Secondary Outcome Measures
The administration of DHEA or pregnenolone will reduce the subjective rewarding effects of nicotine inhaled in cigarette smoke.
The administration of DHEA or pregnenolone will reduce stress-induced changes in mood and craving for cigarettes.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00900900
Brief Title
The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers
Acronym
DHEA
Official Title
The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers
Study Type
Interventional
2. Study Status
Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
March 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jed E. Rose
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will evaluate the potential therapeutic value of two neurosteroid treatments (DHEA and pregnenolone) in the treatment of tobacco withdrawal symptoms. This will include assessing whether these agents relieve craving for cigarettes elicited by exposure to a mildly stressful cognitive task. Pregnenolone (400 mg orally), DHEA (400 mg orally) and placebo will be administered one at each of the three sessions in a randomized order.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Substance Withdrawal Syndrome
Keywords
Cigarette Smokers, DHEA, dehydroepiandrosterone, pregnenolone, Nicotine withdrawal symptoms
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
22 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dehydroepiandrosterone (DHEA)
Arm Type
Experimental
Arm Title
Pregnenolone
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
dehydroepiandrosterone (DHEA)
Intervention Description
one-time 400mg oral dose of DHEA
Intervention Type
Dietary Supplement
Intervention Name(s)
pregnenolone
Intervention Description
one-time 400mg oral dose of pregnenolone
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
one-time dose oral dose
Primary Outcome Measure Information:
Title
The administration of DHEA or pregnenolone will reduce smoking withdrawal symptoms.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
The administration of DHEA or pregnenolone will reduce the subjective rewarding effects of nicotine inhaled in cigarette smoke.
Time Frame
6 months
Title
The administration of DHEA or pregnenolone will reduce stress-induced changes in mood and craving for cigarettes.
Time Frame
6 months
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
male;
18-65 years old;
smoked an average of at least 10 cigarettes per day for three cumulative or continuous years of a brand that delivers (by Federal Trade Commission rated yields) at least 0.5 mg nicotine;
afternoon expired carbon monoxide reading of at least 10 ppm;
in general good health, based on physical examination, EKG serum chemistries, CBC and urinalysis.
Exclusion Criteria:
Participants must not have uncontrolled hypertension (systolic >140 mm Hg, diastolic >95 mm Hg)
hypotension (systolic <90 mm Hg, diastolic <60 mm Hg);
coronary heart disease;
heart attack;
cardiac rhythm disorder (irregular heart rhythm);
chest pains (unless history, exam, and EKG clearly indicate a non-cardiac source);
cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);
liver or kidney disorder (except kidney stones, gallstones);
gastrointestinal problems or disease other than gastroesophageal reflux,
heartburn, or irritable bowel syndrome;
ulcers within the past 6 months;
lung disorder (including but not limited to COPD, emphysema, and asthma);
brain abnormality (including but not limited to, stroke, brain tumor, seizure disorder);
history of fainting;
problems giving blood samples;
diabetes;
current cancer or treatment for cancer in the past 6 months (except basal or squamous cell skin cancer);
other major medical condition;
major depression, panic disorder, anxiety, bipolar disorder, schizophrenia, risk of suicide, or substance dependence other than nicotine dependence;
subjects who endorse suicidal ideation on the MINI abridged;
alcohol or drugs abuse;
reported use of illicit drugs within the past 30 days, or if the drug screen is positive;
reported use of smokeless tobacco (chewing tobacco, snuff), cigars, pipes, or nicotine replacement therapy; testosterone replacement therapy, DHEA or Pregnenolone; experimental (investigational) drugs; psychiatric medications (including antidepressants, anti-anxiety agents. anti-psychotics), sleep aids, medications that increase DHEA and/or DHEA-S concentrations (including, but not limited to: diltiazem, benfluorex, amlodipine, alprazolam, danazol, metformin, nitrendipine and retinol), or any other medications that are known to affect smoking (e.g. clonidine, muscle relaxants, opiate pain medications) within the past 2 weeks.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jed E Rose, Ph.D.
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christine Marx, M.D.
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke Center for Nicotine & Smoking Cessation Research
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Facility Name
Duke Center for Nicotine & Smoking Cessation Research
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27609
Country
United States
12. IPD Sharing Statement
Learn more about this trial
The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers
We'll reach out to this number within 24 hrs